Actemra Subcutaneous Injection (Tocilizumab)
tocilizumab 162 mg/0.9 mL injection, 4 x 0.9 mL syringes · INJECTION · PBS code 11721X
AUTHORITY_REQUIREDWhat it costs
AU$702.33 PBS-determined price per 4 units
Most patients pay only the standard PBS co-payment, not the full price above — up to AU$25.00 per script (general) or AU$7.70 (concession/Safety Net) in 2026. The figure above is what the PBS pays the pharmacy; the Australian Government subsidises the rest. Always confirm the current amount with your pharmacist.
- • First listed on the PBS: 2019-08-01.
- • Repeats: 6.
- • PBS program: GE.
Eligibility criteria for subsidised access
The following is the government's own wording from the PBS Schedule, shown unchanged.
Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1
Active giant cell arteritis
Continuing treatment
Must be treated by a rheumatologist, clinical immunologist or neurologist experienced in the management of giant cell arteritis; AND
Patient must have previously received PBS-subsidised treatment with this drug for this condition; AND
The treatment must not exceed 52 weeks in total including initial and continuing applications.
Sponsor: Roche Products Pty Ltd ABN 70 000 132 865
Not medical advice. Voxsanity republishes public PBS data in plain English. PBS listing status and criteria can change; always confirm current subsidised availability with your doctor or pharmacist.
Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.